...
首页> 外文期刊>Vaccine >Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
【24h】

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.

机译:用MVA85A加强BCG疫苗接种可下调免疫调节细胞因子TGF-beta1。

获取原文
获取原文并翻译 | 示例
           

摘要

In clinical trials recombinant-modified vaccinia virus Ankara expressing the Mycobacterium tuberculosis antigen 85A (MVA85A) induces approximately 10 times more effector T cells than any other recombinant MVA vaccine. We have found that in BCG primed subjects MVA85A vaccination reduces transforming growth factor beta 1 (TGF-beta1) mRNA in peripheral blood lymphocytes and reduces TGF-beta1 protein in the serum, but increases IFN-gamma ELISPOT responses to the recall antigen SK/SD. TGF-beta1 is essential for the generation of regulatory T cells and we see a correlation across vaccinees between CD4+CD25hiFoxP3+ cells and TGF-beta1 serum levels. This apparent ability to counteract regulatory T cell effects suggests a potential use of MVA85A as an adjuvant for less immunogenic vaccines.
机译:在临床试验中,表达结核分枝杆菌抗原85A(MVA85A)的重组修饰痘苗病毒安卡拉(Ankara)诱导的效应T细胞比任何其他重组MVA疫苗多约10倍。我们发现在BCG引发的受试者中,MVA85A疫苗接种可降低外周血淋巴细胞中的转化生长因子β1(TGF-beta1)mRNA,并降低血清中的TGF-beta1蛋白,但会增加对召回抗原SK / SD的IFN-γELISPOT反应。 。 TGF-beta1对于产生调节性T细胞至关重要,我们看到CD4 + CD25hiFoxP3 +细胞与TGF-beta1血清水平之间跨疫苗的相关性。这种明显的抵抗调节性T细胞效应的能力表明,MVA85A作为免疫原性较低的疫苗佐剂的潜在用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号